PODCAST: dr. Efstathios Kastritis about the use of daratumumab in AL amyloidosis

June 2020 EHA 2020 Marjolein Groot

In this podcast dr. Efstathios Kastritis shares the primary results from the ANDROMEDA study examining subcutaneous daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed light chain amyloidosis.